BriaPro subsidiary files financials; spinout of cancer assets completed Aug 31, 2023

BriaCell Therapeutics Corp.

BriaPro filed Jul 31, 2023 financials: $1 cash, zero revenue, inactive during period.
On Aug 31, 2023, BriaPro closed spinout of Bria-TILsRx and PKCδ inhibitors from parent BriaCell.
Spinout consideration: 47,945,178 BriaPro shares issued; BriaCell owns ~31,963,452 (2/3).
BriaCell options/warrants adjusted; 2,131,400 options and 8,121,650 warrants outstanding with split exercise prices.
BriaPro notes going concern uncertainty; will need additional financing to develop assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.